SCHEMBL23356047

SCHEMBL23356047

CC(=O)Nc1n[nH]c2nc(Nc3cccc4c3CCC4)c(F)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ THRA P10827 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NISCH Q9Y2I1 1/20 0.39
▸ RXRA P19793 3/20 0.38
▸ RXRB P28702 3/20 0.38
▸ RXRG P48443 3/20 0.38
▸ PPARA Q07869 3/20 0.38
▸ ALOX5 P09917 2/20 0.38
▸ PPARG P37231 2/20 0.38
▸ EP300 Q09472 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ ULK1 O75385 1/20 0.36
▸ PPARD Q03181 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30791290 1.00 ALDH1A1 (0.42) ALDH1A1L3MBTL1MEN1LMNATHRA
SCHEMBL23356109 0.87 GSK3A (0.47) NISCHULK1
SCHEMBL30791235 0.87 GSK3A (0.47) NISCHULK1
SCHEMBL30791245 0.87 NISCH (0.42) ALDH1A1L3MBTL1MEN1LMNATHRA
SCHEMBL23356090 0.87 NISCH (0.42) ALDH1A1L3MBTL1MEN1LMNATHRA
SCHEMBL23356088 0.86 L3MBTL1 (0.54) ALDH1A1L3MBTL1MEN1LMNAKMT2A
SCHEMBL29874506 0.86 GSK3A (0.47) ULK1
SCHEMBL30791240 0.86 L3MBTL1 (0.54) ALDH1A1L3MBTL1MEN1LMNAKMT2A
SCHEMBL23356124 0.85 RXRA (0.42) ALDH1A1L3MBTL1MEN1LMNATHRA
SCHEMBL23356015 0.84 GSK3A (0.40) ALDH1A1L3MBTL1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 — — US disclosed
CN-112313232-B Novel heterocyclic derivatives JW中外制药公司 2024-03-08 — — CN disclosed
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE JW PHARMACEUTICAL CORPORATION (KR) 2022-08-18 — — US disclosed
EP-3822270-A1 NOVEL HETEROCYCLE DERIVATIVE JW Pharmaceutical Corporation (KR) 2021-05-19 — — EP disclosed
CN-112313232-A Novel heterocyclic derivatives JW中外制药公司 2021-02-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 ALDH1A1 1733/4885L3MBTL1 3665/4885MEN1 3124/4885
US-20220259199-A1 NOVEL HETEROCYCLE DERIVATIVE AR, BRDT, NR5A1 ALDH1A1 734/4885L3MBTL1 4178/4885MEN1 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback